JONATHAN LEI to Cell Line, Tumor
This is a "connection" page, showing publications JONATHAN LEI has written about Cell Line, Tumor.
Connection Strength
0.275
-
Separate endocytic pathways regulate IL-5 receptor internalization and signaling. J Leukoc Biol. 2008 Aug; 84(2):499-509.
Score: 0.043
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
Score: 0.035
-
Comprehensive evaluation of phosphoproteomic-based kinase activity inference. Nat Commun. 2025 May 22; 16(1):4771.
Score: 0.035
-
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer. Mol Ther. 2025 Apr 02; 33(4):1621-1641.
Score: 0.034
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.033
-
Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024 Aug 08; 187(16):4389-4407.e15.
Score: 0.032
-
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A. 2018 12 18; 115(51):E11978-E11987.
Score: 0.022
-
Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
Score: 0.021
-
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 10; 7(10):1168-1183.
Score: 0.020